Market research
BLCM Bellicum Pharmaceuticals Inc
PINK USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 778K
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 1.38
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0794814048
- Market cap
- 778K
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 1.38
About
About Bellicum Pharmaceuticals Inc
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BLCM discussion.
5 years, 4 months ago
Bellicum Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 18.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
Bellicum Pharmaceuticals, Inc's total revenue sank by 90.3% to $500K since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow grew by 99.9% to $-15K since the same quarter in the previous year.
Based on the above factors, Bellicum Pharmaceuticals, Inc gets an overall score of 3/5.